Skip to Main Content

A pair of consumer advocacy groups wants antitrust authorities in Italy and Belgium to investigate Biogen (BIIB) for allegedly abusing its “position in the marketplace” by imposing an “unfair price” for Spinraza, a pricey therapy for treating a rare and fatal childhood disease called spinal muscular atrophy.

In arguing their case, the advocacy groups maintain that there is an “excessive” and “disproportionate” difference between the development costs for the medicine and what the Italian and Belgian health systems are paying. And they want authorities to take action in order to strike a balance between innovation and access.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!